Rosuvastatin inhibits the apoptosis of platelet-derived growth factor-stimulated vascular smooth muscle cells by inhibiting p38 via autophagy

Jun-Hwan Jo, Hyun-Soo Park, Do-Hyung Lee, Joo-Hui Han, Kyung-Sun Heo, and Chang-Seon Myung*

Department of Pharmacology, Chungnam National University College of Pharmacy, Daejeon 34134, Republic of Korea
Running title page

Running title: Anti-apoptotic effect of rosuvastatin via autophagy

Address for correspondence:
Chang-Seon Myung, Ph.D.
Department of Pharmacology
Chungnam National University College of Pharmacy
99 Daehak-ro (St.), Yuseong-gu
Daejeon 34134
Republic of Korea
Tel: +82-42-821-5923
Fax: +82-42-821-8925
E-mail: cm8r@cnu.ac.kr

Number of text page: 22
Number of tables: 0
Number of figures: 8
Number of references: 34
Number of words in the Abstract: 244
Number of words in the Introduction: 574
Number of words in the Discussion: 1090

Abbreviations:
LDL, low-density lipoprotein; VSMCs, vascular smooth muscle cells; PDGF, platelet-derived growth factor; IL-1β, interleukin 1 beta; ERK1/2, extracellular signal-regulated kinase 1/2; ROS, reactive oxygen species; LC3, microtubule-associated proteins 1A/1B light chain 3B; HMG-CoA, 3-hydroxy-3-methyl-glutaryl-coenzyme A; H$_2$DCFDA, 2′,7′-Dichlorofluorescin diacetate; DPPH, 2,2-Diphenyl-1-picrylhydrazyl; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; WST, water soluble tetrazolium; IP, intraperitoneal injection; LCA, left carotid artery; 7-AAD, 7-amino-actinomycin D; FITC, fluorescein isothiocyanate; H&E, haematoxylin and eosin.

Section:
Cardiovascular
Abstract

The secretion of platelet-derived growth factors (PDGFs) into vascular smooth muscle cells (VSMCs) induced by specific stimuli, such as oxidized low-density lipoprotein (LDL) cholesterol, initially increases the proliferation and migration of VSMCs, and continuous stimulation leads to VSMC apoptosis, resulting in the formation of atheroma. Autophagy suppresses VSMC apoptosis, and statins can activate autophagy. Thus, this study aimed to investigate the mechanism of the autophagy-mediated vasoprotective activity of rosuvastatin, one of the most potent statins, in VSMCs continuously stimulated with PDGF-BB, an PDGF isoform to induce phenotypic switching of VSMC, at a high concentration (100 ng/mL). Rosuvastatin inhibited apoptosis in a concentration-dependent manner by reducing cleaved caspase-3 and interleukin (IL)-1β levels and reduced intracellular reactive oxygen species (ROS) levels in PDGF-stimulated VSMCs. It also inhibited PDGF-induced p38 phosphorylation and increased the expression of microtubule-associated protein light chain 3 (LC3) and conversion of LC3-I to LC3-II in PDGF-stimulated VSMCs. The ability of rosuvastatin to inhibit apoptosis and p38 phosphorylation was suppressed by treatment with 3-methyladenine (3-MA; an autophagy inhibitor) but promoted by rapamycin (an autophagy activator) treatment. SB203580, a p38 inhibitor, reduced the PDGF-induced increase in intracellular ROS levels and inhibited the formation of cleaved caspase-3, indicating the suppression of apoptosis. In carotid ligation model mice, rosuvastatin decreased the thickness and area of the intima and increased the area of the lumen.

In conclusion, our observations suggest that rosuvastatin inhibits p38 phosphorylation through autophagy and subsequently reduces intracellular ROS levels, leading to its vasoprotective activity.

Significance statement

This study shows the mechanism responsible for the vasoprotective activity of rosuvastatin in VSMCs under prolonged PDGF stimulation. Rosuvastatin inhibits p38 activation through autophagy, thereby suppressing intracellular ROS levels, leading to the inhibition of apoptosis and reductions in the intima thickness and area. Overall, these results suggest that rosuvastatin can be used as a novel treatment to manage chronic vascular diseases such as atherosclerosis.
Introduction

In addition to stroke and myocardial infarction, atherosclerosis has a high mortality rate throughout the world, and the leading cause of atherosclerotic lesions is low-density lipoprotein (LDL) cholesterol, through which cholesterol is transported through blood vessels (Libby et al., 2019). Complex interactions between vascular smooth muscle cell (VSMC) proliferation and other processes are characteristic of atherosclerotic lesions; lipid deposition in parts of the arteries and endothelial dysfunction lead to the formation of atherosclerotic intima plaques (Lim and Park, 2014). In the progression of atherosclerosis, oxidized LDL cholesterol accumulates in the intima and induces the entrance of monocytes, which are transformed into macrophages that absorb oxidized LDL cholesterol, developing into foam cells, which subsequently secrete platelet-derived growth factor (PDGF) and inflammatory cytokines (Oishi and Manabe, 2016; Cervantes Gracia et al., 2017).

The PDGF-mediated signaling pathway is activated by the binding of each PDGF protein isoform (PDGF-AA, -AB, -BB, -CC, and –DD) to the PDGF receptor. PDGF-BB is one of the most important stimulators of VSMC proliferation and migration in damaged blood vessels (Liu et al., 2005; Ha et al., 2015). Plasma PDGF (PDGF-BB + PDGF-AB) levels were 0.45 ± 0.14 ng/mL in healthy subjects (22), and in patients with essential hypertension (25), these levels increased to 0.63 ± 0.23 ng/mL (Rossi et al., 1998). In addition, excessive and prolonged PDGF-BB stimulation induces apoptosis by producing reactive oxygen species (ROS) (Okura et al., 1998; Park et al., 2018), and apoptosis causes secondary necrosis due to the absence of effective phagocytosis, leading to an increase in plaque rupture by cap thinning (Bennett et al., 2012; Bennett et al., 2016). Therefore, suppression of apoptosis induced by excessive and prolonged stimulation of PDGF-BB is essential for preventing and treating atherosclerosis.

Autophagy is a phenomenon in which cell components such as lipids, proteins, and damaged organelles are recycled through the lysosomal degradation pathway (Yang et al., 2015). Target molecules are sequestered and accumulate in a double-membrane organelle called the autophagosome; the autophagosome then fuses with the lysosome, after which the target molecules are decomposed, and their components recycled (Levine and Kroemer, 2019). In autophagy, microtubule-associated
proteins 1A/1B light chain 3B (LC3) is mainly used as a biomarker (Pugsley, 2017). LC3 is one of the essential substances that form autophagosomes, and LC3 is synthesized and then processed into LC3-I and converted into LC3-II (Tanida et al., 2008). The conversion of LC3-I to LC3-II is related to the extent of autophagosome formation (Kabeya et al., 2000), which means autophagy. Therefore, the measurement of conversion of LC3-I to LC3-II is commonly used for experimental autophagy activity (Park et al., 2018). Autophagy was reported to inhibit apoptosis in blood vessels and protect blood vessels by reducing ROS in PDGF-BB-stimulated VSMCs (Park et al., 2018); therefore, autophagy may be an important therapeutic target for the protection of blood vessels.

Statins, which are used to inhibit cholesterol synthesis by inhibiting 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase, are known to have a wide range of effects, such as their anti-inflammatory, angiogenic and vasoprotective effects (Soulaidopoulos et al., 2018). Statins have also been reported to regulate autophagy (Altwairgi, 2015); however, the exact mechanism of their vasoprotective activity through autophagy is undefined. Thus, this study aimed to clarify the regulatory effect of rosuvastatin, the most potent statin in reducing LDL cholesterol (Lopez, 2003; Karlson et al., 2016), on apoptosis via autophagy in PDGF-stimulated VSMCs. For this purpose, we stimulated VSMCs cultured at maximal confluency with excessive PDGF-BB to induce cell death.

Materials and Methods

Reagents and antibodies. Dulbecco’s modified Eagle medium (DMEM), fetal bovine serum (FBS), trypsin-EDTA, phosphate-buffered saline (PBS) and penicillin/streptomycin were obtained from Gibco Inc. (Grand Island, NY, USA). 2′,7′-Dichlorofluorescin diacetate (H2DCFDA), 2,2'-diphenyl-1-picrylhydrazyl (DPPH), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), N-acetyl-L-cysteine (NAC), and SB203580 were purchased from Sigma-Aldrich (St. Louis, MO, USA). 3-Methyladenine (3-MA) and rapamycin were obtained from Merck Millipore (Billerica, MA, USA). Anti-interleukin-1β (IL-1β) and mouse anti-rabbit IgG-FITC were obtained from Santa Cruz Biotechnology (Dallas, TX, USA). Anti-β-actin and goat anti-rabbit were purchased from AbFrontier (Geumcheon, Seoul, Korea). Anti-phospho-extracellular signal-regulated kinase 1/2
(ERK1/2), anti-ERK1/2, anti-phospho-p38, anti-p38, anti-caspase-3 and anti-microtubule-associated protein light chain 3 (LC3) antibodies were obtained from Cell Signaling Technology (Beverly, MA, USA). Rosuvastatin was obtained from Cayman Chemical (Ann Arbor, MI, USA). PDGF-BB was purchased from Pepro Tech (Rocky Hill, NJ, USA).

**Cell culture.** Rat aortic VSMCs (Cell Applications, Inc.) were cultured in DMEM with 10% FBS, 4.5 g/L D-glucose, 1% penicillin/streptomycin, 2 mM L-glutamine, and 100 mg/L sodium pyruvate at 37°C in a humidified incubator under 5% CO₂. Prior to all experiments, the VSMCs were cultured to full confluency on plates. The experiment was conducted with VSMCs at passages 5-10.

**Animals.** Male C57BL/6 mice at 6 weeks of age (23-25 g) were purchased from Samtako (Osan, Korea) and used to evaluate the vasoprotective activities of rosuvastatin. Prior to the experiment, the animals were acclimated for 1 week. All experimental procedures using animals were performed according to the guidelines of the Chungnam National University Ethics Committee (CNU-00967; Daejeon, Korea).

**Carotid ligation and drug dosing.** A carotid ligation model was induced using male C57BL/6 mice. The mice were anaesthetized by intraperitoneal (IP) injection of 50 mg/kg pentobarbital, and anesthetization was maintained through inhalation of 2.5% isoflurane with oxygen. Afterward, the left carotid artery (LCA) was exposed and completely ligated. Ligation proceeded when there was no physical movement after anesthesia. The mice were treated with 1% ketoprofen to ensure their pain-free recovery. After 5 weeks, the mice were sacrificed through excess pentobarbital, and the carotid arteries and other organs (lung, heart, liver, kidney and spleen) were harvested and fixed in paraffin. The animals were randomly divided into four groups. Animals in the drug-treated experimental groups were orally administered 1 or 10 mg/kg rosuvastatin per day (n=7 per group), and normal saline was administered to both normal mice and model mice subjected to carotid ligation (n=8 per group). Rosuvastatin was administered once a day beginning 2 days before LCA ligation until 5
weeks after ligation.

**Histological analysis.** Serial cross sections (5-μm thickness) throughout the entire length of the LCA were obtained, and staining was performed using hematoxylin and eosin (H&E) (Heo et al., 2014). Computerized morphometric analysis (Image J software; NIH, MD, USA) was used to determine the thickness and area of the intima and media.

**Cell viability assay.** An MTT assay was performed to find the concentration ranges of rosuvastatin and SB203580, which can be used in VSMCs without cytotoxicity. VSMCs were seeded in 96-well plates at a density of 1×10^4 cells per well and cultured in DMEM containing 10% FBS at 37°C and 5% CO_2_. After 48 h, the VSMCs were treated with 2.5-100 μM rosuvastatin, 5 or 10 μM SB203580 and 100 μg/mL digitonin (a positive control) in 0.1% FBS-containing DMEM for 120 or 96 h. Following the culture period, 200 μL of a 5 mg/mL MTT solution was added to each well and incubated for 4 h. After the MTT solution was removed, 200 μL of dimethyl sulfoxide (DMSO) was added to each well. The absorbance at 565 nm was measured with an Infinite M Nano microplate reader (Tecan Group Ltd., Männedorf, Switzerland).

A water-soluble tetrazolium (WST)-8 assay was performed to evaluate the effects of rosuvastatin on cell viability in VSMCs stimulated with PDGF-BB. Because WST-8 assay does not use DMSO, possible cell damage by DMSO can be excluded, and cell viability can be measured more precisely due to its high sensitivity. VSMCs were seeded in 96-well plates at a density of 4×10^4 cells/mL and incubated with DMEM containing 10% FBS at 37°C and 5% CO_2_ for 48 h. The cells were pretreated with 10 or 40 μM rosuvastatin for 24 h, and 10 or 100 ng/mL PDGF-BB was added for 24-96 h. Treatment with rosuvastatin and PDGF-BB was followed by culture in DMEM containing 0.1% FBS. Following the reaction, 100 μL of Quanti-Max WST-8 solution (Biomax, Nowon, Seoul, Korea) was added to the plate. VSMCs were incubated at 37°C and 5% CO_2 for 1 h. The absorbance at 450 nm was then determined using an Infinite M Nano microplate reader (Tecan Group Ltd.).
**Cell apoptosis assay.** The cell apoptosis level was evaluated using the Muse™ Annexin V & Dead Cell Kit from Merck Millipore (Billerica, MA, USA). VSMCs were seeded in 12-well plates at a density of 1.8×10^5 cells per well and incubated in DMEM containing 10% FBS for 42 h. Subsequently, cells were pretreated with 10 or 40 μM rosuvastatin, 100 nM rapamycin, and 50 mM 3-MA for 24 h; 10 or 100 ng/mL PDGF-BB was also added for treatment. After 72 h, the VSMCs were washed in PBS and incubated with 500 μL of a trypsin solution for 3 min. The VSMCs were centrifuged at 5,000 rpm for 5 min. After the supernatant was removed, the pellet was washed with PBS. Staining with Muse™ Annexin V & Dead Cell Kit solution was then performed in the dark for 10 min. Cell apoptosis was measured using a Muse™ Cell Analyzer from Merck Millipore.

**DPPH assay.** A DPPH assay was performed to evaluate the antioxidant activity of rosuvastatin using DPPH solution prepared by mixing methanol and DPPH reagent. DMSO was utilized as a control, and 10 or 40 μM rosuvastatin and 5 mM NAC (as a positive control) were added to cells seeded in 96-well plates. Subsequently, 100 μL of DPPH solution was added to the cells for incubation in the dark. Using an Infinite M Nano microplate reader (Tecan Group Ltd.), the absorbance at 517 nm was measured. Radical inhibition (%) was calculated using the following equation:

\[
\text{Radical inhibition} \, (\%) = \frac{\text{absorbance of negative control} - \text{absorbance of sample}}{\text{absorbance of negative control}} \times 100
\]

**H₂DCFDA assay.** H₂DCFDA was utilized to determine ROS production in VSMCs; VSMCs were seeded in black 96-well plates at a density of 1×10^4 cells per well and cultured. After 48 h, the cells were pretreated with 10 or 40 μM rosuvastatin and 5 or 10 μM SB203580 for 24 h; 10 or 100 ng/mL PDGF-BB was then added for 72 h of incubation. The VSMCs were washed in PBS and incubated with 20 μM H₂DCFDA for 20 min at 37°C. The ROS level was measured using an Infinite M Nano microplate reader (Tecan Group Ltd.) at an excitation wavelength of 485 nm and emission wavelength of 540 nm.
Western blot analysis. A Western blot analysis was performed to measure protein expression levels. Intact VSMCs were washed in cold PBS and lysed with radioimmunoprecipitation assay (RIPA) buffer [50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 2 mM EDTA, 1 mM sodium orthovanadate, 1% NP-40, 5 mM NaF, 1 mM PMSF, 0.1% sodium dodecyl sulfate and 0.5% sodium deoxycholate]. The cell lysate was placed on ice for 30 min and centrifuged for 10 min at 4°C. The amount of protein was measured with a BCA protein assay kit (Pierce, Rockford, IL, USA). Each protein sample was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and proteins were transferred to a polyvinylidene fluoride (PVDF) membrane (ATTO, Tokyo, Japan). The membrane was washed in TBST [10 mM Tris (pH 7.6), 0.1% Tween-20 and 150 mM NaCl] for 10 min; and blocked in TBST mixed with 5% bovine serum albumin (BSA) at 4°C for 1 h. The membrane was then incubated overnight at 4°C with the primary antibody; after washing, the secondary antibody was added and incubated for 6 h. Chemiluminescence (ECL, ATTO Corp., Tokyo, Japan) was utilized to detect specific protein signals. Band densities were quantified with ImageJ software (NIH, MD, USA).

Immunofluorescence staining analysis. Immunofluorescence staining was conducted to measure the expression of LC3 in VSMCs seeded in 24-well plates with coverslips and cultured. After 48 h, the VSMCs were pretreated with rosuvastatin for 24 h and additionally treated with PDGF-BB for 72 h. Following the reaction, the cells were washed twice with cold PBS for 10 min each and fixed with 4% cold formaldehyde. The cells were permeabilized with PBS containing 0.25% Triton X-100 for 3 min and blocked with PBS containing 3% BSA at room temperature. The cells were washed after 1 h with PBS and incubated overnight at 4°C with the primary antibody, followed by additional incubation with anti-FITC antibody at room temperature for 3 h. The nuclei of the VSMCs were stained using 4’,6-diamidino-2-phenylindole (DAPI). Images were captured using a confocal laser scanning microscope (K-1 Fluo, Daejeon, Korea).
Statistical analysis. All data are indicated as the mean ± standard error of the mean (SEM) of three independent experiments. In this study, we used an analysis of variance (ANOVA) to verify the statistical significance of the differences between means in two or more groups, and Dunnett’s test to compare each experimental group with a control. All statistical analyses were conducted using GraphPad Prism (San Diego, CA, USA). A P-value < 0.05 was considered to indicate a statistically significant difference.

Results

Rosuvastatin inhibited apoptosis and the secondary necrosis of VSMCs stimulated with PDGF. VSMCs were pretreated with rosuvastatin before treatment with PDGF-BB, and their increased viability upon rosuvastatin pretreatment was confirmed. The concentration of rosuvastatin used was determined through MTT assay. Rosuvastatin showed no cytotoxicity at concentrations up to 40 μM for 120 h (Fig. 1A). A WST-8 assay was performed to evaluate the impact of rosuvastatin on cell viability. VSMCs were treated with or without 10 or 40 μM rosuvastatin for 24 h; 10 or 100 ng/mL PDGF-BB was then added for 24-96 h of treatment. Following PDGF-BB treatment, the viability of VSMCs treated with 100 ng/mL PDGF-BB remained unchanged after 24 h and 48 h but decreased beginning at 72 h of treatment (Fig. 1B). Additionally, rosuvastatin concentration-dependently increased the viability of VSMCs stimulated with PDGF (Fig. 1B). Afterward, cell death was assessed via quantitative analysis and measurement of cleaved caspase-3 expression. The quantitative analysis was performed using the Muse™ Annexin V & Dead Cell Kit, and the expression of cleaved caspase-3, a critical marker of cell apoptosis (Park et al., 2018), and IL-1β, a critical marker of secondary necrosis (Bennett et al., 2012), was measured using Western blot analysis. In the group incubated with 100 ng/mL PDGF, the increase in cell death induced by PDGF stimulation was inhibited by rosuvastatin in a concentration-dependent manner (Fig. 1C). Rosuvastatin also decreased the expression of cleaved caspase-3 and IL-1β in a concentration-dependent manner (Fig. 1D). These results suggest that rosuvastatin inhibits secondary necrosis by suppressing PDGF-induced apoptosis in VSMCs.
Rosuvastatin reduced the intracellular ROS level in VSMCs stimulated with PDGF. The DPPH radical assay was used to confirm the antioxidant activity of rosuvastatin. Additionally, the H$_2$DCFDA assay was performed to measure changes in intracellular ROS levels induced by PDGF stimulation and rosuvastatin treatment in VSMCs. The DPPH assay was performed by treating VSMCs with 10 or 40 μM rosuvastatin, DMSO (control) or 5 mM NAC (positive control) in 100 μL of a DPPH solution. The H$_2$DCFDA assay was conducted by pretreating VSMCs with 10 or 40 μM rosuvastatin for 24 h before the addition of 10 or 100 ng/mL PDGF-BB for 72 h of culture. The results of the DPPH assay showed that rosuvastatin-treated groups exhibited no changes relative to the control group (Fig. 2A). However, in the case of intracellular ROS levels, the group incubated with 100 ng/mL PDGF-BB exhibited increased ROS levels, but ROS levels decreased as the concentration of rosuvastatin increased (Fig. 2B). These results suggest that rosuvastatin has no free radical-scavenging activity but reduces the level of intracellular ROS produced by PDGF.

Rosuvastatin modulated p38 and LC3 in VSMCs stimulated with PDGF. The expression of apoptosis- and autophagy-associated proteins was quantified to evaluate the effects of rosuvastatin on the mechanisms of apoptosis and autophagy in VSMCs stimulated with PDGF-BB. The phosphorylation of ERK1/2 and p38, which are involved in cell growth and apoptosis (Duan et al., 2016), was measured, and autophagy was confirmed by evaluating the conversion and expression of LC3, a key biological marker of autophagy (Pugsley, 2017). VSMCs were pretreated with rosuvastatin, after which PDGF-BB was added for additional treatment. The levels of ERK1/2 and p38 were confirmed via Western blot analysis, which showed no change in the level of ERK1/2. However, in the case of p38, its expression was reduced by rosuvastatin (Fig. 3A). Quantitative analysis of LC3 was also conducted using Western blot analysis to measure the conversion of LC3-I to LC3-II. Additionally, LC3 levels in VSMCs were observed via immunofluorescence staining. In the group treated with only 100 ng/mL PDGF-BB, the conversion of LC3-I to LC3-II was decreased; however, in the group pretreated with rosuvastatin, an increase in this conversion was observed (Fig. 3B).
Furthermore, compared with the untreated VSMCs, the rosuvastatin-treated VSMCs exhibited increased LC3 expression (Fig. 3C), indicating that rosuvastatin activates autophagy by increasing the expression and conversion of LC3-I to LC3-II in VSMCs.

**Rosuvastatin reduced apoptosis through autophagy in VSMCs stimulated with PDGF.** Quantitative analysis using the Muse™ Annexin V & Dead Cell Kit was conducted to confirm the role of autophagy in apoptosis in VSMCs stimulated with PDGF-BB. The autophagy activator rapamycin and autophagy inhibitor 3-MA were used at 100 nM and 5 mM, respectively, to treat VSMCs pretreated with 40 μM rosuvastatin for 24 h. Then, 100 ng/mL PDGF-BB was further added and incubated for 72 h. For VSMCs in the PDGF group, which were treated with 3-MA and rosuvastatin together, apoptosis increased, and the proportion of live cells decreased compared to that upon treatment with rosuvastatin alone (Fig. 4A). However, when VSMCs were treated with rapamycin, apoptosis decreased, and the proportion of live cells increased (Fig. 4B). These results show that the anti-apoptotic effect of rosuvastatin is mediated through autophagic activity.

**Rosuvastatin inhibited the phosphorylation of p38 through autophagy in VSMCs stimulated with PDGF.** Western blot analysis of cells treated with rapamycin and 3-MA was performed to confirm the level of autophagy and effect of autophagy on p38. VSMCs were pretreated with 40 μM rosuvastatin, 5 mM 3-MA and 100 nM rapamycin for 24 h, after which 100 ng/mL PDGF-BB was added for further treatment for 72 h. Through measuring the conversion of LC3-I to LC3-II, the effects of 3-MA and rapamycin in promoting and decreasing autophagy were confirmed, and the activity of p38 was also observed. The activity of p38 increased when autophagy was inhibited (Fig. 5A) and decreased when autophagy was activated (Fig. 5B).

**Suppression of intracellular ROS levels and apoptosis by p38 inhibition.** SB203580, a specific inhibitor of p38 phosphorylation, was used to treat VSMCs to confirm the regulation of intracellular ROS levels and apoptosis medium by p38. The MTT assay was used to determine the concentration of
SB203580 used in the experiment. The intracellular ROS level, both with and without p38 phosphorylation inhibition, and cleaved caspase-3 expression were confirmed. SB203580 did not show cytotoxicity at concentrations up to 10 μM (Fig. 6A). Therefore, VSMCs were pretreated with 40 μM rosuvastatin and 5 or 10 μM SB203580 for 24 h. Subsequently, 100 ng/mL PDGF-BB was added for an addition 72 h. The results showed that SB203580 reduced the intracellular ROS level in PDGF-BB stimulated VSMCs (Fig. 6B) and decreased the expression of cleaved caspase-3, a key marker of cell apoptosis, in VSMCs stimulated with PDGF (Fig. 6C).

Vasoprotective effect of rosuvastatin shown in a mouse model of carotid ligation. Carotid ligation has been reported to increase the secretion of inflammatory cytokines and growth factors, thus stimulating the proliferation and migration of VSMCs (Heo et al., 2014). Therefore, a mouse model of carotid ligation was used to evaluate the occurrence of atherosclerosis due to the proliferation and migration of VSMCs. The body weights of the mice were not changed over the experimental period (data not shown), and the thickness and area of the intima and media were measured to determine the effect of rosuvastatin. In the case of media, there was no difference in its thickness or area. However, 10 mg/kg rosuvastatin administration diminished the ligation-induced change in the thickness and area of the intima (Fig. 7). Therefore, high dose of rosuvastatin (10 mg/kg) reduced intima-media thickness (IMT) and increased the area of the lumen in a ligated carotid artery mouse model.

Discussion

Atherosclerosis and its complications are some of the leading causes of death worldwide. For many years, atherosclerosis has been classified primarily as a lipid-induced disease characterized by lipid deposits on blood vessels, and research continues to focus on its prevention; however, the risk of complications remains high, and millions of people worldwide suffer from these complications each year (Schaftenaar et al., 2016). VSMCs are a cell type that constitutes blood vessels; however, their excessive proliferation, migration, and apoptosis induced by PDGF and inflammatory cytokines secreted from foam cells contribute to the development of atherosclerosis (Basatemur et al., 2019;
Libby et al., 2019). Therefore, investigating the apoptosis of VSMCs in atherosclerosis is essential for developing treatment strategies.

The present study proposes a mechanism for the activity of rosuvastatin: rosuvastatin inhibits VSMC apoptosis caused by excessive and prolonged PDGF stimulation. Rosuvastatin was confirmed to inhibit the apoptosis of VSMCs induced by PDGF-BB. Our study showed the upregulation of LC3 and inhibition of p38 phosphorylation by autophagy activation. Through inhibiting p38 phosphorylation, intracellular ROS levels and apoptosis were reduced.

Statins are a class of drugs generally used to treat and prevent hyperlipidemia in cardiovascular patients. Because statins are mainly used in combination with other medications, their potential drug-drug interactions should be considered (Wiggins et al., 2016). This study examined rosuvastatin, which exhibits better potency than other statins (Lopez, 2003; Karlson et al., 2016). The effect of rosuvastatin on autophagy in cancer and neuroinflammation has been studied (Zeybek et al., 2011; McFarland et al., 2018). Previous study has shown that atorvastatin, one of the statin family, protects VSMCs from calcification induced by transforming growth factor-β1 (TGF-β1) stimulation by inducing autophagy through inhibition of the β-catenin pathway (Liu et al., 2014). However, information on the mechanism by which rosuvastatin affects PDGF-BB-stimulated VSMC apoptosis via autophagy was insufficient, necessitating the current study.

PDGF-BB induces the proliferation and migration of VSMCs in the early stages of vascular disease (Ha et al., 2015), but cell apoptosis is induced when excessive stimulation with PDGF-BB is applied for long periods (Okura et al., 1998). Moreover, due to the absence of efficient phagocytosis, apoptotic VSMCs induce secondary necrosis (Bennett et al., 2012). Thus, cell death was assessed using Annexin V and 7-amino-actinomycin D (7-AAD) (Muse™ Annexin V & Dead Cell Kit) as markers of dead VSMCs (Zembruski et al., 2012). PDGF-BB increased VSMC apoptosis and necrosis in a time- and concentration-dependent manner (Fig. 1B & C). In addition, to evaluate apoptosis and secondary necrosis (caused by persistent apoptosis), the expression of cleaved caspase-3 and cleaved IL-1β was determined. The expression of cleaved caspase-3 (a major marker of apoptosis) was increased, and that of IL-1β (a major marker of secondary necrosis) was also increased by PDGF-BB.
stimulation (Fig. 1D). Simultaneously, rosuvastatin was found to concentration-dependently inhibit apoptosis and secondary necrosis induced by PDGF-BB (Fig. 1). The phosphorylation of p38, which is involved in the apoptosis pathway (Duan et al., 2016), was reduced by rosuvastatin (Fig. 3A). VSMCs induced apoptosis and thus secondary necrosis via prolonged stimulation with excessive PDGF-BB, whereas rosuvastatin reduced apoptosis by inhibiting the phosphorylation of p38.

Since the apoptosis of VSMCs induced by PDGF stimulation is accompanied by the generation of oxidative stress (Park et al., 2018), we evaluated the antioxidant activity of rosuvastatin by measuring its free radical-scavenging ability and intracellular ROS levels. As a result of the DPPH assay, which was used to measure free radical scavenging (Sirivibulkovit et al., 2018), rosuvastatin was confirmed to lack significant free radical-scavenging activity (Fig. 2A). Intracellular ROS levels, measured through the H$_2$DCFDA assay (Oparka et al., 2016), were initially increased by PDGF-BB stimulation and then decreased by rosuvastatin treatment (Fig. 2B). These results indicate that rosuvastatin has an anti-apoptotic effect exerted by lowering the intracellular ROS level in VSMCs stimulated with PDGF.

In previous studies, autophagy was reported to regulate survival and function in VSMCs (Dong et al., 2019); thus, we examined the regulatory effect of rosuvastatin on autophagy. Rosuvastatin increased the expression of LC3 (Fig. 3C) and conversion of LC3-I to LC3-II (Fig. 3B). Furthermore, autophagy was confirmed to inhibit the apoptosis of VSMCs through the regulation of autophagy using 3-MA and rapamycin (Fig. 4). The phosphorylation of p38 was also inhibited by autophagy (Fig. 5). Thus, rosuvastatin inhibits p38 phosphorylation through autophagy, which can reduce apoptosis.

Using SB203580 (a specific inhibitor of p38 phosphorylation) (Yan et al., 2016), an experiment to determine whether the phosphorylation status of p38 affects intracellular ROS levels and apoptosis was conducted. Inhibition of p38 phosphorylation was confirmed to decrease the PDGF-induced increase in intracellular ROS level (Fig. 6B) and expression of cleaved caspase-3 (Fig. 6C). These results suggest that p38 phosphorylation status is related to the regulation of intracellular ROS and apoptosis induced by PDGF stimulation.

Intima and media thickness and area are now increasingly used experimentally as factors to assess the risk of atherosclerosis (Touboul et al., 2004; Park et al., 2017). In particular, IMT is known as a
useful marker for predicting the occurrence of cardiovascular events (Touboul, 2015), and is also used experimentally to evaluate carotid artery blood flow and luminal alteration in carotid ligation animal model (Zhang et al., 2015). Therefore, we also used an established neointima formation model induced by carotid artery ligation to determine whether rosuvastatin would affect VSMCs proliferation in vivo (Brown et al., 2018). In a mouse model of carotid artery ligation, the media thickness and area were not altered by rosuvastatin, but the ligation-induced increases in intima thickness and area were diminished by rosuvastatin, thus increasing the area of the lumen, without toxicity (Fig. 7). In this study, in vitro experiments we used PDGF-BB with a high concentration of about 100 ng/mL, and the issue that this amount of PDGF-BB in cell levels is relevant to cause increased intimal thickness in vivo experiments is another part of research. In future studies, it may be necessary to compare plasma PDGF levels with control in the carotid ligation mouse model (or balloon-injury model) that causes neointima formations in experimental animals.

In conclusion, our study focused on the autophagy-mediated effect of rosuvastatin on VSMC apoptosis induced by PDGF stimulation. Our results indicated that rosuvastatin reduced intracellular ROS and apoptosis by inhibiting the phosphorylation of p38 via autophagy in PDGF-stimulated VSMCs (Fig. 8). In addition, it could suppress secondary necrosis caused by apoptosis accordingly. Therefore, the mechanism of rosuvastatin through autophagy could suggest a novel pathway for the treatment of vascular diseases such as atherosclerosis and restenosis in patients for whom conventional treatments have not been effective.

Authorship Contributions

Participated in research design: JH Jo, HS Park, CS Myung
Conducted experimental: JH Jo, HS Park, DH Lee, JH Han, CS Myung
Contributed new reagents or analytic tools: KS Heo
Performed data analysis: JH Jo, HS Park, CS Myung
Wrote or contributed to writing of the manuscript: JH Jo, CS Myung
References


Differences in statin associated neuroprotection corresponds with either decreased production of IL-1 beta or TNF-alpha in an in vitro model of neuroinflammation-induced neurodegeneration. *Toxicol Appl Pharm* 344:56-73.


**Footnotes**

This work was supported by the National Research Foundation of Korea (KRF), funded by the Ministry of Science and ICT (grant no. NRF-2018R1A2A2A05023578).

**Conflict of interest**

No author has an actual or perceived conflict of interest with the contents of this article.

**Figure legends**

**Figure 1.** Effect of rosuvastatin on the viability of VSMCs stimulated by PDGF

(A) The concentration of rosuvastatin used for subsequent experiments was determined through MTT assay. VSMCs were treated with rosuvastatin (2.5-100 μM) for 120 h. Digitonin (100 μg/mL) was used as a positive control (PC). (B) VSMCs were treated with rosuvastatin (10 or 40 μM) for 24 h, after which PDGF-BB (10 or 100 ng/mL) was added for an additional 24, 48, 72 or 96 h. VSMC viability was measured via WST-8 assay. (C) VSMC death was evaluated using the Muse™ Annexin V & Dead Cell assay. (D) The expression of cleaved caspase-3 (a key marker of cell apoptosis) and IL-1β (a key marker of secondary necrosis by apoptosis) was measured via Western blot analysis. The gel images are representative of three similar independent experiments. Data are expressed as the mean ± SEM. *p < 0.05; **p < 0.01 vs no treated control, #p < 0.05; ##p <0.01 vs PDGF-BB (100 ng/mL)-treated control. n=3 per group.
Figure 2. The free radical-scavenging ability of rosuvastatin and its effect on intracellular ROS levels in VSMCs stimulated with PDGF

(A) The DPPH assay was used to assess the free radical-scavenging ability of rosuvastatin. The DPPH assay was performed by treating VSMCs with rosuvastatin (10 or 40 μM), DMSO as a control, or NAC (5 mM) as a positive control with 100 μL of a DPPH solution. (B) Rosuvastatin reduced PDGF-BB-stimulated intracellular ROS levels. VSMCs were incubated with rosuvastatin (10 or 40 μM) for 24 h and additionally treated with PDGF-BB (10 or 100 ng/mL) for 72 h. VSMCs were treated with H$_2$DCFDA (20 μM). Data are expressed as the mean ± SEM. **p < 0.01 vs DMSO control, ##p < 0.01 vs PDGF-BB (100 ng/mL)-treated control. n=3 per group.

Figure 3. Effect of rosuvastatin on ERK1/2, p38 and LC3 levels in VSMCs stimulated with PDGF

Protein expression levels were measured using Western blot analysis. VSMCs were incubated with rosuvastatin (10 or 40 μM) for 24 h and then additionally treated with PDGF-BB (10 or 100 ng/mL) for 72 h. (A, B) The effects of rosuvastatin on cell growth, apoptosis-associated protein (Erk1/2 and p38) levels and the conversion of LC3-I to LC3-II in VSMCs stimulated with PDGF-BB are shown. The gel images are representative of three similar independent experiments. Data are expressed as the mean ± SEM. *p < 0.05 vs no treated control, #p < 0.05; ##p < 0.01 vs PDGF-BB (100 ng/mL)-treated control. (C) LC3 was observed via confocal microscopy. Immunofluorescence staining was conducted with anti-LC3 and anti-FITC secondary antibodies. Cell nuclear staining was performed using DAPI. Scale bar = 30 μm. n=3 per group.

Figure 4. Anti-apoptotic effect of rosuvastatin via autophagy in VSMCs stimulated with
The anti-apoptotic effect of rosuvastatin was confirmed through autophagy inhibition and activation. (A) The autophagy inhibitor 3-MA (5 mM) was used with rosuvastatin (40 μM) to pretreat VSMCs for 24 h. PDGF-BB (100 ng/mL) was added for an additional 72 h of treatment. (B) The autophagy activator rapamycin (100 nM) was used with rosuvastatin (40 μM) to pretreat VSMCs for 24 h. PDGF-BB (100 ng/mL) was added for an additional 72 h of treatment. The effects of autophagy inhibition (A) and activation (B) on apoptosis were measured through the Muse™ Annexin V & Dead Cell assay. Data are expressed as the mean ± SEM. *p < 0.05 vs no treated control, #p < 0.05; ##p < 0.01 vs PDGF-BB (100 ng/mL)-treated control, §p<0.05; §§p < 0.01 vs PDGF-BB (100 ng/mL) + rosuvastatin (40 μM)-treated group. n=3 per group.

**Figure 5.** Effect of rosuvastatin on p38 via autophagy in VSMCs stimulated with PDGF

The effect of rosuvastatin on the activity of p38 was confirmed through autophagy inhibition and activation. (A) The autophagy inhibitor 3-MA (5 mM) was used with rosuvastatin (40 μM) to pretreat VSMCs for 24 h. PDGF-BB (100 ng/mL) was added for an additional 72 h of treatment. (B) The autophagy activator rapamycin (100 nM) was used with rosuvastatin (40 μM) to pretreat VSMCs for 24 h. PDGF-BB (100 ng/mL) was added for an additional 72 h of treatment. Changes in protein expression due to autophagy inhibition (A) and activation (B) were evaluated via Western blot analysis. The gel images are representative of three similar independent experiments. Data are expressed as the mean ± SEM. *p < 0.05; **p < 0.01 vs no treated control, #p < 0.05; ##p < 0.01 vs PDGF-BB (100 ng/mL)-treated control, §p < 0.05 vs PDGF-BB (100 ng/mL) + rosuvastatin (40 μM)-treated group. n=3 per group.
**Figure 6.** Suppression of intracellular ROS levels and apoptosis by p38 inhibition

SB203580, a p38 inhibitor, was used to treat VSMCs. (A) The concentration of SB203580 used for the experiment was determined through MTT assay. Digitonin (100 µg/mL) was used as a positive control (PC). (B) The H$_2$DCFDA assay was used to measure intracellular ROS levels. VSMCs were pretreated with SB203580 (5 or 10 µM), after which PDGF-BB (100 ng/mL) was added for an additional 72 h. (C) Cleaved caspase-3 levels and the phosphorylation of p38 were measured via Western blot analysis. The gel images are representative of three similar independent experiments. Data are expressed as the mean ± SEM. **p < 0.01 vs no treated control, ##p < 0.01 vs PDGF-BB (100 ng/mL)-treated control. n=3 per group.

**Figure 7.** Effect of rosuvastatin on the intima and media in a mouse model of carotid ligation

Low- or high-concentration rosuvastatin was orally administered beginning 2 days before ligation until 5 weeks after ligation. The body weights of the mice were not changed over the experimental period (data not shown). Five weeks after ligation, the carotid artery was harvested and fixed in paraffin, and H&E staining was performed. The thickness and area of the intima, media and lumen were measured. The images shown are representative of those obtained from eight independent experiments. Data are expressed as the mean ± SEM (n=8 for each experimental group). *p < 0.05; **p < 0.01 vs control (Con). IEL (internal elastic lamina), EEL (external elastic lamina), Sham (unligated), Con (ligated, no rosuvastatin treatment), Low (ligated, 1 mg/kg/day rosuvastatin), High (ligated, 10 mg/kg/day rosuvastatin).

**Figure 8.** Rosuvastatin reduces intracellular ROS level and apoptosis by inhibiting...
phosphorylation of p38 via autophagy in PDGF-BB stimulated VSMCs.
<table>
<thead>
<tr>
<th>PDGF-BB (ng/mL)</th>
<th>Rosuvastatin (μM)</th>
<th>3-MA (mM)</th>
<th>PDGF-BB (ng/mL)</th>
<th>Rosuvastatin (μM)</th>
<th>Rapamycin (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>100</td>
<td>40</td>
<td>5</td>
<td>100</td>
<td>40</td>
<td>100</td>
</tr>
<tr>
<td>100</td>
<td>40</td>
<td>5</td>
<td>100</td>
<td>40</td>
<td>100</td>
</tr>
<tr>
<td>100</td>
<td>40</td>
<td>5</td>
<td>100</td>
<td>40</td>
<td>100</td>
</tr>
</tbody>
</table>

**A)**
- p-p38
- p38
- LC3-I
- LC3-II
- β-actin

**B)**
- p-p38
- p38
- LC3-I
- LC3-II
- β-actin

**Relative density level**
- **A)**
  - p-p38
  - LC3

- **B)**
  - p-p38
  - LC3